Company intelligence / Profile preview

Dharma Therapeutics, Inc.

Seattle, Washington, USAprnewswire.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Completed Phase 1 and Phase 2 clinical trials demonstrating that the IDDS system safely and effectively delivers lidocaine and epinephrine transdermally to provide rapid topical anesthesia during venipuncture procedures. The device showed an excellent safety profile with minimal adverse events reported. In both trials, pain was significantly reduced compared to controls.

Therapeutic areas: Other
Modalities: Transdermal drug delivery via iontophoresis
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

lidocaine + epinephrine

Phase 1

Indications: Local anesthesia, Pain management

Partnerships

Lifetree Clinical Research® conducted clinical trials in the US under FDA IND.

Beyond the preview

Go deeper on Dharma Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dharma Therapeutics, Inc..

Explore the full profile